Indivior and Supernus Complete $3.4 Billion Pharmaceutical Merger

Indivior and Supernus Pharmaceuticals completed their approximately $3.4 billion merger on 2 November, creating a combined business focused on central nervous system medicines. The transaction highlights opportunities for pharmaceutical suppliers, healthcare consultants, clinical research providers and medical technology companies. HPC can support healthcare partnerships, supplier identification and pharmaceutical market research.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.